Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Personalis (NASDAQ:PSNL) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

A number of other analysts also recently issued reports on the company. Guggenheim assumed coverage on Personalis in a research report on Thursday, May 15th. They set a “buy” rating and a $6.00 price objective for the company. HC Wainwright cut their price objective on Personalis from $9.00 to $8.50 and set a “buy” rating for the company in a research report on Wednesday, August 6th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.42.

Personalis Trading Down 0.2%

Shares of NASDAQ:PSNL opened at $4.50 on Friday. The business has a 50-day moving average price of $6.08 and a 200 day moving average price of $4.89. The company has a market capitalization of $399.06 million, a price-to-earnings ratio of -3.52 and a beta of 1.86. Personalis has a 12-month low of $2.83 and a 12-month high of $7.79.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $17.20 million during the quarter, compared to the consensus estimate of $20.12 million. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%. As a group, equities research analysts predict that Personalis will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

A number of hedge funds and other institutional investors have recently bought and sold shares of PSNL. Lightspeed Management Company L.L.C. purchased a new position in Personalis during the 4th quarter valued at about $47,169,000. Aberdeen Group plc boosted its holdings in Personalis by 472.3% during the 1st quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock valued at $5,984,000 after acquiring an additional 1,406,895 shares during the period. Geode Capital Management LLC boosted its holdings in Personalis by 165.6% during the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after acquiring an additional 851,422 shares during the period. ARK Investment Management LLC boosted its holdings in Personalis by 6.1% during the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company’s stock valued at $25,231,000 after acquiring an additional 412,762 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Personalis by 144.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock valued at $2,372,000 after acquiring an additional 242,141 shares during the period. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.